Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 3/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.35 |
| ▸ | TTK | P33981 | 5/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30385667 | 0.96 | PTK6 (0.33) | PTK6PTK2TTK | |
| SCHEMBL24112510 | 0.94 | PTK2 (0.37) | PTK6PTK2TTKAURKB | |
| SCHEMBL32675691 | 0.92 | PTK2 (0.33) | PTK6PTK2TTK | |
| SCHEMBL24112401 | 0.91 | PTK6 (0.33) | PTK6PTK2TTKAURKB | |
| SCHEMBL22122899 | 0.91 | PTK2 (0.41) | PTK6PTK2TTKAURKBERBB2 | |
| SCHEMBL24112489 | 0.91 | PTK6 (0.33) | PTK6PTK2TTK | |
| SCHEMBL24112501 | 0.91 | PTK2 (0.34) | PTK6PTK2TTK | |
| SCHEMBL25451174 | 0.90 | TTK (0.39) | PTK6PTK2TTK | |
| SCHEMBL24112321 | 0.89 | TTK (0.33) | PTK6PTK2TTKAURKBTBK1 | |
| SCHEMBL25173554 | 0.88 | PTK2 (0.35) | PTK6PTK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | claimed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885PTK2 3799/4885TTK 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.